Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter B Gilbert

Showing results (151-160 of 337) with videos related to

Pageof 34
Sort By:
Violence and Victims|October 12, 2023
Violence Exposure Among Women in the Sex Industry and Their Children in El Alto, Bolivia: A Comparative Cross-Sectional StudyLara Antkowiak, Renée Boynton-Jarrett, Silvia S Chiang, et al.
Scientific Reports|November 9, 2022
Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategyLue Ping Zhao, Terry P Lybrand, Peter B Gilbert, et al.
The Journal of Infectious Diseases|March 16, 2011
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trialsPeter B Gilbert, James O Berger, Donald Stablein, et al.
Vaccine|August 8, 2006
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluationFusheng Li, Uma Malhotra, Peter B Gilbert, et al.
Human Vaccines & Immunotherapeutics|April 24, 2018
Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trialsYunda Huang, Shelly Karuna, Lindsay N Carpp, et al.
Plos One|January 21, 2017
Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical StructureMohammed S Aiyegbo, Evgeny Shmelkov, Lorenzo Dominguez, et al.
Scientific Reports|April 19, 2018
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling studySimon de Montigny, Blythe J S Adamson, Benoît R Mâsse, et al.
The Journal of Infectious Diseases|May 20, 2015
Reply to DunningPeter B Gilbert, Erin E Gabriel, Michael G Hudgens, et al.
Vaccine|July 2, 2021
Evidence for antibody as a protective correlate for COVID-19 vaccinesKristen A Earle, Donna M Ambrosino, Andrew Fiore-Gartland, et al.
Mabs|April 4, 2017
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adultsYunda Huang, Lily Zhang, Julie Ledgerwood, et al.
Pageof 34

Showing results (151-160 of 337) with videos related to

Sort By:
Pageof 34
Violence and Victims|October 12, 2023
Violence Exposure Among Women in the Sex Industry and Their Children in El Alto, Bolivia: A Comparative Cross-Sectional StudyLara Antkowiak, Renée Boynton-Jarrett, Silvia S Chiang, et al.
Scientific Reports|November 9, 2022
Rapidly identifying new coronavirus mutations of potential concern in the Omicron variant using an unsupervised learning strategyLue Ping Zhao, Terry P Lybrand, Peter B Gilbert, et al.
The Journal of Infectious Diseases|March 16, 2011
Statistical interpretation of the RV144 HIV vaccine efficacy trial in Thailand: a case study for statistical issues in efficacy trialsPeter B Gilbert, James O Berger, Donald Stablein, et al.
Vaccine|August 8, 2006
Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluationFusheng Li, Uma Malhotra, Peter B Gilbert, et al.
Human Vaccines & Immunotherapeutics|April 24, 2018
Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trialsYunda Huang, Shelly Karuna, Lindsay N Carpp, et al.
Plos One|January 21, 2017
Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical StructureMohammed S Aiyegbo, Evgeny Shmelkov, Lorenzo Dominguez, et al.
Scientific Reports|April 19, 2018
Projected effectiveness and added value of HIV vaccination campaigns in South Africa: A modeling studySimon de Montigny, Blythe J S Adamson, Benoît R Mâsse, et al.
The Journal of Infectious Diseases|May 20, 2015
Reply to DunningPeter B Gilbert, Erin E Gabriel, Michael G Hudgens, et al.
Vaccine|July 2, 2021
Evidence for antibody as a protective correlate for COVID-19 vaccinesKristen A Earle, Donna M Ambrosino, Andrew Fiore-Gartland, et al.
Mabs|April 4, 2017
Population pharmacokinetics analysis of VRC01, an HIV-1 broadly neutralizing monoclonal antibody, in healthy adultsYunda Huang, Lily Zhang, Julie Ledgerwood, et al.
Pageof 34